Methods for non-invasive detection of transplant health or rejection

ABSTRACT

The present invention relates to the technical field of organ and tissue transplantation and specifically to methods allowing rejection of transplanted organs and tissues by a transplant patient. The present invention provides methods for non-invasive and ex vivo or in vitro detection of the presence or absence of transplant rejection, i.e. transplant health or rejection. The present methods allow for effective and continuous monitoring of transplant status with a minimal or absent discomfort for a transplant patient.

The present invention relates to the technical field of organ and tissuetransplantation and specifically to methods allowing detection ofrejection of transplanted organs and tissues by a transplant patient ororgan recipient/acceptor. The present invention provides methods fornon-invasive, i.e. ex vivo or in vitro, detection of the presence orabsence of transplant rejection, i.e. transplant health. The presentmethods allow for effective and continuous monitoring of transplantstatus with a minimal, or absent, discomfort for a transplant patent,i.e. an organ recipient or acceptor.

Organ transplantation is the transfer of an organ or tissue from a donorbody or patient to a recipient body or patient for the purpose ofreplacing the recipient's damaged or absent organ or tissue. Transplantsbetween two subjects of the same species, such as humans, are designatedas allografts. Allografts can either be from a living or cadavericsource.

Examples of organs that can be transplanted are the heart, kidneys,liver, lungs, pancreas, intestine, and thymus. Examples of tissuesinclude bones, tendons (both referred to as musculoskeletal grafts),cornea, skin, heart valves, nerves and veins. Worldwide, kidneys are themost commonly transplanted organs, followed by liver and heart. Corneaand musculoskeletal grafts are the most commonly transplanted tissues;these outnumber organ transplants by more than tenfold.

Transplantation medicine is one of the most challenging and complexareas of modern medicine. Some of the key areas for medical managementare transplant rejection mainly due to an immune response against thetransplanted organ. Such immune response often results transplantfailure or transplant rejection and the need to immediately remove thetransplanted organ or tissue from the recipient or acceptor. Whenpossible, the chance of transplant rejection or failure can be minimizedthrough serotyping in order to determine the most appropriatedonor-recipient/acceptor match possibly in combination with the use ofimmunosuppressant drugs.

Kidney transplantation is generally considered for patients withend-stage renal disease (ESRD), regardless of the primary cause. Commondiseases leading to ESRD include malignant hypertension, infections,diabetes mellitus, and focal segmental glomerulosclerosis; geneticcauses include polycystic kidney disease, a number of inborn errors ofmetabolism, and autoimmune conditions such as lupus. Diabetes is themost common cause of kidney transplantation, accounting forapproximately 25% of patients in the United States (US). The prevalenceof ESRD in the US and developed nations is alarmingly high anddramatically increased compared to previous decades. Currently,haemodialysis, peritoneal dialysis and kidney transplantation are theonly available therapies for ESRD. The majority of renal transplantrecipients are on dialysis (peritoneal dialysis or hemofiltration) atthe time of transplantation. However, individuals with chronic renalfailure who have a living donor available may undergo pre-emptivetransplantation before dialysis is needed.

Kidney transplantation is a life-extending procedure. Based on a threeto four year follow-up period, the long term mortality for transplantpatients was estimated to be 68% lower than that of patients notreceiving a transplant. Kidney transplantation is typically classifiedas deceased-donor or living-donor transplantation depending on thesource of the donor organ. Living-donor renal transplants are furthercharacterized as genetically related (living-related) or non-related(living-unrelated) transplants, depending on whether a biologicalrelationship is present between the donor and recipient. The averagelifetime for a donated kidney is twelve to fifteen years.

The major barrier for organ transplantation between geneticallynon-identical individuals is the recipient's immune system, which willtreat the transplanted kidney as an “invader” and immediately orchronically reject it. Therefore, it is essential to administermedication to suppress the immune system after transplantation. In thelast two decades, the available number of immunosuppressive agents hasincreased greatly. Agents can be used as induction therapy (at the timeof transplant), as maintenance therapy (to prevent rejection of theallograft), or for treatment of acute rejection.

Recommendations for immunosuppressive medications are necessarilycomplex, because combinations of multiple classes of immunosuppressivedrugs are used and because the choice among different regimens aredetermined by the trade-offs between benefits and harm. Typically, agreater degree of immunosuppression may reduce the risk of rejection,but may also increase the risk of infection and cancer. Standard posttransplantation therapy consists of a calcineurin inhibitor,antiproliferative agents, and corticosteroids. The calcineurininhibitors, cyclosporine and tacrolimus, are a mainstay of maintenanceimmunosuppression. They inhibit IL-2 transcription, and suppresseffector T-cells. Both have similar side effects, such as new-onsetdiabetes after transplantation, hyperlipidemias, hypertension,osteopenia and a decreased glomerular filtration rate. They both alsocause significant nephrotoxicity.

The antiproliferative agents, mycophenolate mofetil, mycophenolic acid,and azathioprine, often cause diarrhea and gastrointestinal discomfortand may be associated with an increased risk of tissue-invasive CMV.They are used in combination with aforementioned drugs for maintenanceof immunosuppression. Corticosteroids have traditionally been a mainstayof maintenance immunosuppression in kidney transplant recipients.Prednisolone suppresses the immune system, but its long-term use at highdoses causes a multitude of side effects, including glucose intoleranceand diabetes, weight gain, osteoporosis, muscle weakness,hypercholesterolemia, and cataract formation. Prednisolone alone isusually inadequate to prevent rejection of a transplanted kidney.

Kidney transplantation is the treatment of choice for patients withESRD, improving survival and quality of life and lowering costs ofdialysis as stated above. However, the alloimmune response induced bytransplantation from a donor who differs genetically from the kidneyrecipient remains a major obstacle to graft success. Recipient factors,donor factors, and donor/recipient compatibility all influence thelong-term graft survival.

Superior graft survival has been established in recipients/donors whoare younger, have spent less time on dialysis. Also race and ethnicitymay affect graft survival. Kidneys from living (related or non-related)donors survive longer on average than deceased donor kidneys.Pre-sensitized patients have developed antibodies againsthistocompatibility antigens as a result of blood transfusions,pregnancy, or prior failed transplant. These antibodies are called panelreactive antibodies (PRA). Low PRA levels indicate a greater chance ofgraft success. Finally, factors of donor and recipient compatibilityalso affect outcomes: better HLA matching, CMV serologic status matchingand equivalent donor/recipient BMI all have positive effects onlong-term graft survival.

Worldwide, approximately 63.000 patients yearly receive a kidneytransplant. In Europe in 2013, a total of 4.400 kidney transplants wereperformed of which 3000 from deceased donors and 1400 patients fromliving donors.

Since the demand for transplant kidneys far exceeds the supply ofavailable organs, there is a long waiting list. The median time totransplant for new candidates ranges between 1100 to 1200 days. In anattempt to shorten the waiting list, donor organs have been expanded to‘marginal’ kidneys. These so called expanded criteria donor (ECD)kidneys are derived from normally aged 60 years or older, or over 50years with at least two of the following conditions: hypertensionhistory, serum creatinine >1.5 mg/dl or cause of death fromcerebrovascular accident.

The risk of graft loss has traditionally been divided into an early,high-risk period and a later period of constant low risk. Short-termgraft survival risks include delayed allograft function, HLA antibodies,type of donor kidney (living donor vs. deceased, expanded donorcriteria), donor illness (cardiovascular, donor age (higher risk >60y)), and other factors. Long-term risk factors are an increased serumcreatinine concentration, proteinuria, and increased pulse pressure.

Chronic rejection and allograft loss are more likely to develop inpatients with a history of acute rejection, a greater degree of HLAmismatching, infection, and/or inadequate immunosuppressive therapy.Through the use of immunosuppression and better immunologic matching ofrecipients with donors, the overall risk of acute rejection within 1year after transplantation is now approximately 15%.

It is important to diagnose a rejection as early as possible in order toadapt the treatment to save the allograft. Therefore, there is acritical need for non-invasive detection and prediction methods that canbe used in the early detection of allograft rejection. The currentdiagnostic criteria of transplant rejection will be discussed below.

Transplanted patients are very closely monitored in the first threemonths after transplantation through extensive clinical and laboratorybased monitoring to detect signs of rejection. Currently, a rejection isdiagnosed based on both measuring biochemical parameters with a lowdiagnostic specificity, such as serum creatinine, and the pathologicalfindings on a renal biopsy. A rise in serum creatinine points torejection; although a subclinical rejection may be apparent only afterkidney biopsy and can, in absence of renal dysfunction, damage theallograft. Rejection can be hyper acute (within minutes aftertransplantation), acute (within days to weeks), late acute (after 3months), or chronic (months to years after transplantation).

A biopsy is taken when an allograft rejection is suspected, based on arise in serum creatinine. However, a number of factors, such as theoriginal quality of the donated organ, ischemia, acute and subclinicalrejection, chronic humoral rejection, and effect of CNI-inducednephrotoxicity, will adversely affect renal structure, causing earlytubular atrophy and interstitial fibrosis, followed by arteriolarhyalinosis, arteriosclerosis, and glomerular sclerosis, beforecreatinine levels start to rise.

Consequently, there is not a reliable correlation between serumcreatinine and kidney damage. At the point that the level of serumcreatinine goes up, the glomerular filtration rate may already beseverely reduced. For this reason, the serum creatinine test isn'tuseful in diagnosing early-stage kidney damage. In addition, few wellperformed studies are available on the sensitivity and specificity ofserum creatinine concentrations after kidney transplantation. Today,biopsy analysis from the kidney allograft remains the golden standard todiagnose rejection and other graft-associated pathologies.

Although kidney allograft biopsies allow for diagnosis of graftpathology, it is unpractical, labor-intensive, costly and not withoutrisk for the patient, i.e. the recipient or acceptor.

Therefore, there is a critical need in the art for non-invasivedetection and prediction methods that can be used in the early detectionof allograft rejection allowing frequent monitoring of the renal graftwithout any morbidity to the patient.

Given the low sensitivity of the existing biochemical biomarkers and therisk and cost associated with renal biopsies as allograft monitoringtools, it is clear that novel, risk free and affordable biomarkers areneeded to monitor allograft health after transplantation.

A class of biomarkers that may fulfil these requirements were discoveredmore than 60 years ago with the observation that the bloodstream ofevery individual contains (circulating) cell free DNA or (c)cfDNA andthat increased levels of cfDNA appear to be associated with a number ofclinical disorders.

Over the past 15 years, there has been increasing interest in the use ofcfDNA in plasma and urine samples for molecular diagnostics, especiallyfor cancer detection and prenatal diagnosis. Typically, cfDNA has a sizerange between 50 and 200 bp as a result of DNA nuclease digestion of thereleased DNA. In 1998, it was shown that donor-derived DNA sequenceswere present in the plasma of transplant recipients. This group furthershowed that different transplanted organs e.g., the heart, liver, andkidney appeared to release different amounts of DNA into the plasma,probably related to the size of the organ.

As cell death is generally accepted to be an important reason for therelease of DNA into the plasma, it was further hypothesized that themeasurement of donor-derived DNA in the plasma of transplant recipientsmight be used for monitoring graft rejection because donor-derived cfDNAwas detected in the recipient's blood and urine after solid organallograft transplantation. It has been shown that urinary cfDNA afterrenal transplantation has patient specific thresholds, reflecting theapoptotic injury load of the donor organ. Serial monitoring of urinarycfDNA can thus be a sensitive biomarker of acute injury of the donororgan.

To date, most experiments were performed in female patients transplantedwith a male donor organ. As such, the presence of donor-derived cfDNAwas measured by amplification of a Y-linked gene (e.g. TSPY1, SRY). Thisgender analysis prevents the wide-spread use of cfDNA as a diagnostictool, because female recipients of male donor organs represent less thana quarter of all transplant procedures.

A qPCR based test that specifically detects polymorphisms in the HLAregion of the donor derived HLA alleles was shown to enable donorderived cfDNA detection. Although this strategy has broader populationcoverage than the above-mentioned sex-mismatched strategy, itnonetheless requires specific assays to be designed for eachdonor-recipient pair.

The recent availability of single molecule counting techniques allowsdetection of donor kidney derived cfDNA. Hereto, informative SNPs arerequired, i.e. SNPs that are homozygous in the recipient and eitherheterozygous or homozygous for the other allele in the donor. Digitaldroplet PCR and MPS are both single molecule counting methods, whichallow quantification of nucleic acids by counting molecules and havesuperior analytical precision compared to conventional PCR or qPCR baseddetection methods.

Digital droplet PCR refers to the performance of multiple PCRs inparallel in which each PCR typically contains either a single or notarget molecule. Counting the number of positive reactions at the end ofthe amplification allows determining the number of input targetmolecules. Recently, a novel digital droplet PCR method was described toquantify donor DNA in the recipient's blood. Hereto, a set of 41 SNPassays (minor allele frequency [MAF] >40%), was used which first wereanalyzed on the genomic DNA of the recipient to determine homozygousSNPs. All homozygous SNPs were subsequently used to genotype therecipient's cfDNA enabling the measurement of the donor cfDNA fractionby using a hydrolysis based SNP assay in combination with digitaldroplet PCR.

Analysis of 27 cfDNA samples showed that donor organ derived cfDNA wassuccessfully detected in all patients and showed that the number ofobtained informative SNPs ranged between 2 and 9 with an average of 3informative SNPs per patient.

For digital PCR, quantitative precision improves with increasing numberof PCR analyses performed. Therefore, several thousands digital PCRsneed to be performed, requiring the use of automated platforms. Suchautomated platforms using microfluidics are available (e.g. Fluidigm)but are expensive.

Massively parallel sequencers allow analysis of nucleotide sequences ofmillions to billions of DNA molecules in each run. Therefore, inaddition to the identity, a frequency distribution of the DNA moleculesin the analyzed sample can be obtained. Since cfDNA in plasma isfragmented in nature it can be used directly to identify the origin ofeach DNA molecule and determine the proportion of molecules derived fromthe donor organ.

A paper published in 2011 showed that universal non-invasive monitoringof organ transplant health can be performed using MPS on plasma derivedcfDNA from hart transplant patients. Hereto, sequencing adaptors wereligated to the cfDNA which was subsequently sequenced on an IllumniaGAII platform generating 15 to 20 million reads per sample.

The resulting 36 bp reads were mapped to the human reference genome andunique reads spanning a SNP were used to calculate the donor derivedcfDNA fraction taken into consideration the a priori determinedgenotypes on the donor's and recipient's genomic DNA using a SNP array.The donor DNA percentage was calculated by taking twice the number ofdonor heterozygous read calls plus the number of donor homozygous readcalls over the total number of donor and recipient read calls. Onaverage about 0.001% of the total number of generated MPS reads can beused to calculate the SNP based donor derived cfDNA fraction.

Using the above described method, the authors demonstrated thatdonor-derived cfDNA exists in the plasma of organ transplant recipients,and that elevated levels of donor DNA can be used as an indication oforgan rejection. Their data establish unambiguously that donor-specificDNA is present in the plasma of heart transplant recipients and that thelevel of donor specific cfDNA represents mean values of 1% of the totalcfDNA fraction. During organ rejection, however, the level of donor DNAsignal rises with values increasing up to 5% of the total cell-free DNA.

The main advantage of this method is that it can be used for alldonor-recipient pairs. Thus, this strategy may have a more generalapplicability than previous approaches based on Y-chromosomal markersand genetic markers in the HLA region. The potential disadvantage ofthis approach is costliness MPS and the complexity of the subsequentbioinformatics analysis compared with conventional PCR-based detectionstrategies. The cost issue is further compounded by the fact thattesting at multiple time points may be needed for a particulartransplant recipient for monitoring purposes. The costs associated withMPS are falling rapidly, however, and it is likely that the cost will nolonger be a substantial issue in a few years time.

Nevertheless, since a substantial number of sequences need to begenerated of which only a small fraction is used to determine the healthof a transplant organ, this method will hamper simultaneous analysis oflarge numbers of samples and/or will require high end, expensive,sequencers resulting in substantial investment in equipment andspecialized personnel to efficiently perform the required number ofanalyses.

Considering the above, it is an object of the present invention, amongstobjects, to at least partially obviate the above problems associatedwith organ and tissue transplantation.

The above object of the present invention, amongst other objects, is metby methods for non-invasive detection of transplant health or rejectionin a recipient of a tissue or organ from a donor as outlined in theappended claims.

Specifically, the above object, amongst other objects is met by thepresent invention by methods for non-invasive detection of transplanthealth or rejection in a recipient of a tissue or organ from a donor,the method comprises the steps of:

-   -   a) amplifying at least 250 amplicons by nucleic acid        amplification wherein each amplicon comprises a Single        Nucleotide Polymorphism (SNP) thereby providing amplified        amplicons wherein said amplification is performed on at least        one sample A of said acceptor and at least one sample of said        donor or, in the alternative, on at least one sample A of said        acceptor;    -   b) determining the nucleic acid sequence of said amplified        amplicons from said at least one sample A of said acceptor and        determining the nucleic acid sequence of said amplified        amplicons from said at least one sample of said donor or, in the        alternative, determining the nucleic acid sequences of said        amplified amplicons of said acceptor and said donor from said at        least one sample A and determining donor discriminating        amplicons;    -   c) determining the presence of donor discriminating amplicons in        a sample B of said recipient by nucleic acid amplification of        cell free DNA (cfDNA) wherein the presence or amount of        amplified donor discriminating amplicons in said sample B is        indicative for transplant health or rejection. According to a        preferred embodiment, the present amplification in step (a) is a        multiplex Polymerase Chain Reaction (PCR).

According to another preferred embodiment, the present nucleic acidamplification in step (c) is a multiplex Polymerase Chain Reaction(PCR).

According to yet another preferred embodiment of the present method, thepresent amplification in step (a) is a multiplex Polymerase ChainReaction (PCR) and the present nucleic acid amplification in step (c) isa multiplex Polymerase Chain Reaction (PCR).

According to an especially preferred embodiment of the present methoddetermining the nucleic acid sequence in step (b) is performed usingmassively parallel sequencing; or determining the presence of donordiscriminating amplicons in step (c) is performed using massivelyparallel sequencing; or determining the nucleic acid sequence in step(b) is performed using massively parallel sequencing and determining thepresence of donor discriminating amplicons in step (c) is performedusing massively parallel sequencing.

According to another especially preferred embodiment, step (c) of thepresent method further comprises that the amount of donor discriminatingamplicons is determined, wherein the amount is indicative for detectionof transplant health or rejection.

The present method is preferably used for assaying transplant health orrejection of transplants selected from the group consisting of heart,blood vessel, gland, esophagus, stomach, liver, gallbladder, pancreas,intestines, colon, rectum, endocrine gland, kidney, ureters, bladder,spleen, thymus, spinal cord, ovaries, uterus, mammary glands, testes,vas deferens, seminal vesicles, prostate, pharynx, larynx, trachea,bronchi, lungs, diaphragm, bone, cartilage, ligament, tendon and partsand tissues thereof.

According to still another preferred embodiment of the presentinvention, the present at least one sample of said donor is a biopsy ofsaid transplanted tissue or organ.

According to a more preferred embodiment of the present method, thepresent sample B is derived from blood, urine, faces or sputum, such aswhole blood, serum or plasma.

The present method is especially suitable for detecting acute or chronictransplant rejection, such as transplant rejection caused bygraft-versus-host disease.

According to a most preferred embodiment, present step (c) is repeatedat different time-points after receiving said tissue or organ from saiddonor thereby providing continuous monitoring of transplant health orrejection.

The present invention will be further illustrated in the followingexample outlined a most preferred embodiment of the present invention.

EXAMPLE

The NIOTT MASTR assay was being used throughout this example toexemplify the concept for targeted, multiplex amplification of SNPcontaining amplicons in combination with MPS to enable monitoring of thedonor cfDNA fraction in blood and urine derived from recipient cfDNA.

The design of the NIOTT MASTR assay is based on the current NIAT MASTRassay, which comprises 6.592 SNP containing amplicons. The NIAT MASTRassays was used to analyze >200 blood derived cfDNA samples frompregnant women and thus generated a wealth of information on theperformance of each of the amplicons present in the assay. Based on thisinformation a set of 1000 SNP containing amplicons was selected toestablish the NIOTT MASTR assay. The minimal amplicon selection criteriawere:

-   -   Amplicons with least amplification variation;    -   Amplicons with most efficient amplification;

-   A—Amplicons devoid of allele specific amplification bias.

The optimization steps were based on the reiterative adjustment ofindividual primer concentrations in the multiplex PCR assay. The NIOTTMASTR optimization process consists of the following steps:

-   -   1. Add all 2000 primers to one vial at the same concentration.    -   2. Verify amplification efficiency of each amplicons by MiSeq        based MPS on 8 DNA samples.    -   3. Based on the resulting read counts for each amplicon,        increase primer concentration of amplicons showing less        efficient amplification.    -   4. Reiterate steps 2 and 3 until the read counts of all        amplicons are within one standard deviation.

Based on the individual primer pair concentrations obtained from theoptimization phase, two independent NIOTT MASTR assay batches wereproduced and evaluated by MiSeq based MPS on 4 DNA samples. One batchwas produced for 500 NIOTT tests and a second batch was produced todeliver 2000 NIOTT tests.

In order to take full advantage of the power of targeted amplificationwith the NIOTT assay in combination with MPS, it is required to obtainthe genotypes of both the donor and the recipient. Hereto, blood derivedgenomic DNA was used as template DNA for amplification with the NIOTTMASTR assay. The resulting NIOTT amplification product was subsequentlysequenced on a MiSeq at low amplicon coverage. Based on experience witha germ line MASTR assay it was shown that an average amplicon coverageof 100 read counts is sufficient to unambiguously determine heterozygousvariants. Therefore, to generate the donor and recipient genotypesapproximately 100.000 reads per sample were required, corresponding to0.5% of the capacity of a MiSeq run with the current sequencingchemistry.

For each patient, urine and blood samples were collected at ten fixedtime points at days 1, 3, 7, 14, 21, 28, 42, 56, 70 and 90post-transplantation. This will result in total of 1400 samples; 700blood samples and 700 urine samples. cfDNA isolation, NIOTTamplification and MPS analysis of all these samples is for budgetary andlogistics reasons not feasible. Therefore, a pilot study was performedto evaluate the best cfDNA source, i.e. cfDNA derived from urine or fromblood. The best cfDNA source is defined as the source that provides thehighest total cfDNA yield and the highest donor cfDNA fraction.

For this pilot experiment, from urine and blood samples from 35transplant patients cfDNA was extracted, NIOTT amplified and MPSanalyzed for all ten time points, resulting in 700 cfDNA samples. Thetotal cfDNA yield from each cfDNA extraction was spectrophotometricdetermined. Subsequent, MPS data analysis enabled quantification of thedonor cfDNA fraction. The results from the pilot experiment enableddetermining which cfDNA source is significantly better performing. Incase cfDNA extraction from blood and urine are equivalent in yield anddonor fraction a decision for the preferred source is to be made basedon economical and clinical considerations. In both cases this will leadto the decision to select one of both cfDNA sources for the NIOTT proofof concept on the remaining transplant patients.

After selection of the best cfDNA source, the sampling and cfDNAextraction procedure for newly included patients and/or samples wererestricted to the best cfDNA source only.

It is essential to determine the post transplantation evolution of thedonor cfDNA fraction since no published study evaluated this in detail.The few MPS based studies performed show that the donor cfDNA fractionin a healthy transplant is below or at 1% of the total cfDNA fraction.Furthermore, a recent study showed that the donor cfDNA fraction can bevery high, up to 90% of the total cfDNA fraction, in the first day posttransplantation dropping sharply to baseline level after a few days.

To confirm this observation the data generated from all sample timepoints obtained from the 35 patients was used. The results of thisanalysis had three main consequences:

-   -   (i) if the presence of a high donor cfDNA fraction in the first        days post transplantation can be confirmed than this allows        determination of the donor genotype directly from the recipient        sample post transplantation. The consequence being that it is no        longer required to obtain a tissue samples from the kidney donor        which can be difficult in cases when the donor is deceased;    -   (ii) if a high donor cfDNA fraction is present in the first days        post transplantation than this will hamper identification of        acute kidney rejection which typically occur in the first few        days post transplantation;    -   (iii) the longitudinal analysis of the 35 patients will allow        determination of the baseline cfDNA fraction per individual        patient and at the same time will allow determination of the        baseline variance between transplant patients.

To substantiate the results obtained, all transplant patients were used.Hereto, the cfDNA from the best source of the remaining 35 patients wasused to obtain NIOTT data resulting in the generation of 350 MPSdatasets.

All participating patients were subjected to the standard of caremonitoring tools. To evaluate if the NIOTT/MPS method can serve as anuniversal technology for the early detection of kidney rejection, it isessential to show that kidney rejection can be detected substantiallyearlier than with the conventional monitor tools. Hereto, the urine orblood samples for all ten time points of patients that show signs ofkidney rejection based on the current monitoring tools, were used todetermine the donor cfDNA fraction with the NIOTT/MPS technology. Theresulting data will allow determining the effectiveness of cfDNA asbiomarker for the pre-clinical detection of kidney rejection. Also, itwill allow determining the sensitivity and specificity of the NIOTT/MPSbased procedure in predicting kidney rejection.

Sequencing was performed on MiSeq and NextSeq500 Illumina sequencers.MiSeq based sequencing will be used to generate the genotypes of thedonor and recipient genomic DNA. A total of 140 samples was sequenced togenerate all genotypes which corresponds to 1 MiSeq run using the V3sequencing chemistry. Also, MiSeq capacity is required to optimize andproduce the NIOTT assay as described. A total of 6 MiSeq runs wasrequired to successfully perform this task.

The 1150 cfDNA samples that require sequencing were sequenced on theNextSeq 500. Assuming 2×10⁶ reads per samples and a NextSeq 500 runcapacity of 400×10⁶ reads, a total of 6 NextSeq 500 runs are required.

To allow cross MPS platform validation a set-up of 100 samples were runon both the MiSeq and NextSeq 500 sequencers. Since the run capacity perMiSeq is 25×10⁶ reads and 2×10⁶ per sample this will require 8 MiSeqruns.

Based on current experience with the NIAT assay in combination withIllumina sequencing, the following workflow was utilized to determinevariant frequencies of data generated with the NIOTT assay:

-   -   1) Trim adapter sequence: The NIOTT amplicons are between 65 and        85 bp long. Due to the read length on MiSeq or HiSeq (typically        1×75 bp), adapter sequences are often partially present at the        3′-end of the sequenced reads. These adapter sequences are        removed using cutadapt, resulting in better alignment results        and allowing primer dimer sequences to be removed.    -   2) Remove primer dimer sequences: After adapters are trimmed,        sequenced reads should be at least 65 bp long (the minimal        amplicon size). Sequences shorter than 65 bp are considered as        primer-dimer sequences and are discarded from the dataset. The        NIAT assay has shown that the fraction of primer dimer sequences        in the total dataset acts as an important sample quality        parameter reflecting input DNA concentration and DNA        fragmentation.    -   3) Align reads to the NIOTT reference set, using Bowtie2.    -   4) Call variants: Each of the amplicons is designed to contain        one known SNP which is roughly located in the middle of the        amplicon. Variants within amplicons on positions other than the        designed polymorphic site are discarded. This approach strongly        simplifies data analysis and allows sequencing errors to be        separated from genuine variants, even at low variant        frequencies.

Once variants and variant frequencies were determined, the donor cfDNAfraction was calculated. Following variant frequency determination,there are two options, depending on availability of data and theresearch question (longitudinal study or single time point analysis).

-   1) Genotype of both donor and recipient are available: Observed    variant frequencies in cfDNA are matched to donor and recipient    genotype using a maximum likelihood approach where the donor cfDNA    fraction is the variable of interest. The donor cfDNA fraction is    computationally varied from 0 to 100%. As the genotype of both donor    and acceptor are known, expected cfDNA mixtures (a set of SNP    frequencies) can be calculated for each of these cfDNA fractions.    The cfDNA fraction of the expected cfDNA mixture best matching the    observed cfDNA mixture is the estimated cfDNA fraction.-   2) Genotype of both donor and acceptor are not available: since the    donor cfDNA fractions in a healthy kidney transplant patient are    typically very low, SNPs present uniquely in the donor (either    heterozygous or homozygous), can easily be discriminated from    recipient SNPs. The evolution of these SNPs frequencies through time    can be used to calculate the evolution of donor cfDNA fraction in a    longitudinal study.

Many different samples will be sequenced after applying the NIOTT assay.Some of these samples will be involved in a longitudinal analysis.Furthermore, MPS generates a vast amount of data, increasing the needfor a structured approach regarding data handling, storage andannotation. To avoid human interaction, inherent introduction of humanerror and to reduce the risk of losing or switching datasets, all datawill be maintained in a dedicated database system.

1. A method for non-invasive detection of transplant health or rejectionin a recipient of a tissue or organ from a donor, the method comprisesthe steps of: a) amplifying at least 250 amplicons by nucleic acidamplification wherein each amplicon comprises a Single NucleotidePolymorphism (SNP) thereby providing amplified amplicons wherein saidamplification is performed on at least one sample A of said acceptor andat least one sample of said donor or at least one sample A of saidacceptor; b) determining the nucleic acid sequence of said amplifiedamplicons from said at least one sample A of said acceptor anddetermining the nucleic acid sequence of said amplified amplicons fromsaid at least one sample of said donor or determining the nucleic acidsequences of said amplified amplicons of said acceptor and said donorfrom said at least one sample A thereby determining donor discriminatingamplicons; c) determining the presence of donor discriminating ampliconsin a sample B of said recipient by nucleic acid amplification of cellfree DNA (cfDNA) wherein the presence or amount of amplified donordiscriminating amplicons in said sample B is in
 2. Method according toclaim 1, wherein said amplification in step (a) comprises a multiplexPolymerase Chain Reaction (PCR). indicative for transplant health orrejection
 2. The method according to claim 1, wherein said amplificationin step (a) comprises a multiplex Polymerase Chain Reaction (PCR). 3.The method according to claim 1, wherein said nucleic acid amplificationin step (c) comprises a multiplex Polymerase Chain Reaction (PCR). 4.The method according to claim 1, wherein said determining the nucleicacid sequence in step (b) is performed using massively parallelsequencing.
 5. The method according to claim 1, wherein said determiningthe presence of donor discriminating amplicons in step (c) is performedusing massively parallel sequencing.
 6. The method according to claim 1,further comprising, in step (c), determining the amount of donordiscriminating amplicons, said amount is indicative for detection oftransplant health or rejection.
 7. The method according to claim 1,wherein said tissue or organ is selected from the group consisting ofheart, blood vessel, gland, esophagus, stomach, liver, gallbladder,pancreas, intestines, colon, rectum, endocrine gland, kidney, ureters,bladder, spleen, thymus, spinal cord, ovaries, uterus, mammary glands,testes, vas deferens, seminal vesicles, prostate, pharynx, larynx,trachea, bronchi, lungs, diaphragm, bone, cartilage, ligament, tendonand parts and tissues thereof.
 8. The method according to claim 1,wherein said at least one sample of said donor is a biopsy of saidtransplanted tissue or organ.
 9. The method according to claim 1,wherein said sample B is derived from blood, urine, faces or sputum. 10.The method according to claim 9, wherein said sample is whole blood,serum or plasma.
 11. The method according to claim 1, wherein saidtransplant rejection is caused by acute or chronic transplant rejectionby said recipient.
 12. The method according to claim 1, furthercomprising repeating step (c) at different time-points after receivingsaid tissue or organ from said donor.
 13. The method according to claim1, wherein said at least 250 amplicons is at least 500, at least 1000,at least 1500 or at least 2000 amplicons.